Accession Therapeutics presented some of the exciting preclinical data for our lead programme #TROCEPT-01 at the recent 37th Annual Meeting of the @Society for Immunotherapy of Cancer. Working with our partners at @Cardiff University we demonstrated the potential of #TROCEPT products to generate high concentrations of potent anti-tumour drugs selectively in cancer cells with minimum systemic toxicity. In in vitro and in vivo studies #TROCEPT-01 was shown to traffic to tumour